Audit: QRS - Zeolite for Health & Longevity

Audit conducted on 12/09/2026 23:34 using AI4L / Opus 5

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Verified item by item against the ER: at-a-glance vs `Conclusion`, protocol cells vs `Therapeutic Protocol`, time cells vs `Practical Considerations`, benefit/risk tiers vs the ER tier headings, gates vs `Key Interactions & Contraindications`, and all 12 markers plus cadence vs `Monitoring Protocol & Defining Success`.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious framing is carried over intact, e.g. “Almost every human study came from companies selling it” mirrors the ER `Conclusion`, and `marker_12_target` keeps “No established target; track change from the individual’s own baseline”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and interactions retain the ER’s severity level; the chelation item keeps “(specialist supervision)”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits come only from `Expected Benefits`, risks only from `Potential Risks & Side Effects`, gates only from `Key Interactions & Contraindications`; no modifying factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, expert names, NCT identifiers or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears anywhere in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, conflict-of-interest-aware register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining readable; targets and thresholds are given without hedging.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence and thresholds; no prescriptive instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advice framing; the protocol cells describe what trials and practitioners did.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Descriptive throughout, e.g. “Trials used 1.85–9 g daily…”, “Splitting maintains binding capacity…”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the QRS body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain wording throughout; the few technical terms (eGFR, zonulin, oxaliplatin) are the ER’s own and are unavoidable in a monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Every cell is a condensed phrase; no sentence exceeds one line of content.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address of the reader.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes an adult prepared to test metals and minerals and to monitor over months.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Presents four-hour dose separation, batch certificates of analysis and repeated panels without softening the burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not framed for a casual consumer; the sheet is built around testing and monitoring.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance explicitly weighs the manufacturer-funding problem and non-selective binding against the lead-binding signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Formal register throughout; “Standard oral dose” is used for route of administration, and “after drinking” is the ER’s own benefit heading.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings and Monitoring column headers are byte-identical to the template; tier labels Medium / Low / Speculative are unchanged, and the High labels are absent only because the spans are hidden per 12.5 / 13.5.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans are present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_* (4), stop_items, caution_items, risks_* (4), marker_#name/target/why expanded to marker_1–12, monitoring_cadence, and qualitative_item# expanded to qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff against the template shows changes only inside variable spans and the metadata block; CSS, structure, website=”…” spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No section of the source ER is empty; the ER’s High-tier benefit and risk subsections carry explanatory prose, and the QRS handles them per 12.5 / 13.5 (display:none).
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels are reused verbatim: “Standard oral dose”, “Split rather than single dosing”, “Best time of day”, “Narrow therapeutic index drugs”, “Antibiotics and anti-seizure medication”, “Over-the-counter medications”, “Mineral supplements”, “Other binders”, “Chelation therapy”.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is invented; the three time-to-effect labels are drawn from the ER’s own “Time to effect” bullet, and all 12 marker names match the ER table exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji appear in the QRS; the ER’s 🟩 / 🟥 / 🟨 / ⚠️ / ⭕️ markers were all stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed relative to the ER — tier items reduced to semicolon lists, gate items to key facts, qualitative items to their leading clause — and no content spills into a second sheet.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens on line 2, directly after `<!doctype html>`, before any other comment or `<html>` content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	The YAML block opens at line 3 and closes at line 13, inside the single comment.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is enclosed in an HTML comment and is not echoed by any visible element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values are trimmed and unquoted except `duration: "00:03"`, which contains a colon and therefore requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: `er_filename: zeolite_2026-0912-2103_Opus_ER.md`, matching the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: `qrs_prompt_version: 26.9.11`, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: `qrs_creation_date: 2026-0912-2328`, in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: `qrs_creator_ai_nickname: Opus`.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: `qrs_creator_ai_fullname: Opus 5`.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: `qrs_filename: zeolite_2026-0912-2103_Opus_QRS.html`, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: no stray whitespace and no unnecessary quoting in any frontmatter value.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	Line 22: `Zeolite for Health & Longevity - Quick Reference Sheet`, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	Line 417: `Zeolite for Health & Longevity`, matching the ER `canonical_topic`.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: `09/12/2026`, the MM/DD/YYYY form of qrs_creation_date 2026-0912.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: `Opus 5`, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header is byte-identical to the template apart from the three variable spans; no badge, AKA line or audit stamp was added.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Condenses the ER `Conclusion` into mechanism, strongest finding, evidence-base caveat, key trade-off and cost/burden verdict.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the five clauses maps to a distinct `Conclusion` passage: gut-restricted and unabsorbed; lead-binding as the strongest finding; manufacturer funding; non-selective binding; cheap and low-burden for those who test and monitor.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist classifications; “digestive tract”, “bloodstream” and “minerals” are used in place of technical equivalents.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect size, relative risk or statistic appears; “sharply reduces” replaces the ER’s ~90% figure.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All six items trace to the ER’s “Populations who should avoid Zeolite” list in `Key Interactions & Contraindications`.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-populations are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six `<li>` elements inside the `stop_items` span (lines 564–572).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale clauses are stripped in every item, e.g. “, given the reported immune-cell shifts” and “, where mobilised metals and aluminium clear poorly”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The clinical staging qualifier is preserved: “eGFR below 30 mL/min/1.73 m² (stage 4–5)”; the only dropped parentheses are plain-language glossary definitions, not qualifiers.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s `Key Interactions & Contraindications` section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, which is correct: the ER names six populations that should avoid the intervention.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty; six contraindication items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All six items trace to the ER’s interaction bullets in `Key Interactions & Contraindications`.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The six ER interaction bullets are represented; none duplicates a contraindication item.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Six `<li>` elements inside the `caution_items` span (lines 580–602).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity / Consequence / Mitigation prose is stripped throughout, and the em-dash glosses on “Narrow therapeutic index drugs”, “Other binders” and “Chelation therapy” are removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs are carried through for every class (levothyroxine, warfarin, digoxin, lithium; doxycycline, ciprofloxacin, phenobarbital; omeprazole, famotidine; cholestyramine, colesevelam; succimer, DMPS, calcium-disodium EDTA), trimmed rather than dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s `Key Interactions & Contraindications` section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, which is correct: the ER names six interaction classes.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty; six interaction items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	All three action cells trace to the ER `Therapeutic Protocol` bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose, dose splitting and timing are the three implementable levers; the remaining ER bullets are product-brand descriptions, pharmacokinetic notes and modifying factors.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER `Therapeutic Protocol` section supplies three or more distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All nine action fields carry substantive ER-derived content (lines 449–487).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The three cells reproduce the ER `Practical Considerations` “Time to effect” bullet in full.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from the Medium-tier lead-binding effect (immediate), through the Low-tier bowel and lipid effects (4–8 weeks), to the Low-tier bone and metal-profile changes (months to years).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry substantive ER-derived content (lines 497–526).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER provides time-to-effect information in `Practical Considerations`; the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All tier contents trace to the ER `Expected Benefits` headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables are present (lines 535–554).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of benefit headings with no magnitude, attribution or mechanism.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s parenthetical and emoji markers, including “⚠️ Conflicted” and “⭕️ Not Central to Health & Longevity”, are stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 535: `<span data-qrs-var="benefits_high" style="display: none"></span>`, correctly hidden rather than filled with empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	All tier contents trace to the ER `Potential Risks & Side Effects` headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables are present (lines 614–631).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of risk headings with no frequency, attribution or mechanism.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content from the ER risk headings or magnitudes is carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 614: `<span data-qrs-var="risks_high" style="display: none"></span>`, correctly hidden rather than filled with empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	The table reproduces the ER `Monitoring Protocol & Defining Success` biomarker table.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All 12 ER biomarker rows are present with their optimal functional ranges and reasons: blood lead, whole blood cadmium/arsenic/mercury, serum copper, serum zinc, serum sodium, albumin-corrected serum calcium, ferritin, creatinine and eGFR, ALT and AST, complete blood count, fasting lipid panel, stool zonulin.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Populated with the ER cadence: baseline, three months, twelve months, then every six to twelve months, with lipids rechecked at eight weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	The five items trace to the qualitative-marker list at the end of the ER `Monitoring Protocol & Defining Success` section.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All five ER qualitative markers are present: stool frequency and consistency, abdominal pain and bloating days, constipation, energy and exercise tolerance, cognitive clarity and mood.

Issues 12/09/2026 23:34

Pass rate 100.00%. No issues found.